GLP1 + Cagrilintide Research Administration Common Study Populations Clinical trials have enrolled diverse participant groups: Adults with obesity BMI 30 kg/m squared or greater without diabetes (REDEFINE 1) Adults with overweight and comorbidities BMI 27 kg/m squared or greater with at least one weight-related condition Adults with type 2 diabetes BMI 27 kg/m squared or greater with established diabetes (REDEFINE 2) Age range Primarily adults aged 18-75 years across trials Geographic diversity Multi-national trials across North America, Europe, Asia, and other regions Exclusion criteria typically included type 1 diabetes, recent cardiovascular events, severe renal or hepatic impairment, history of pancreatitis, and medications causing significant weight changes
Ahangar N, Naderi M, Noroozi A et al (2017) Zinc deficiency and oxidative stress involved in valproic acid induced hepatotoxicity: Protection by zinc and selenium supplementation
References : [1] [3] [4] [5] [6] National Library of Medicine, Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data, Pickart, L., Margolina, A., July 2018 [2] National LIbrary of Medicine, The potential of GHK as an anti-aging peptide, Dou, Y., Lee, A., Zhu, L., Morton, J., Ladiges, W., March 2020
Glutathione does not regulate hormones directly and does not cure PCOS